The incretin effect was measured as the difference in insulin levels in response to oral and to an isoglycemic iv glucose load. 用肠促胰岛素的效应来检测口服葡萄糖和同等血糖静脉葡萄糖负荷后胰岛素水平的不同。
BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 ( GLP-1). 百泌达与人类肠激素&胰高血糖素样肽(GLP-1)作用类似。
Conclusions: These data suggest that early after GBP, the greater GLP-1 and GIP release and improvement of incretin effect are related not to weight loss but rather to the surgical procedure. 研究结论:这些数据显示胃旁路手术早期胰高血糖素样肽-1和胰高血糖素的大量释放以及肠促胰岛素效应的增加和体重减轻没有关系而是和手术操作有关。
In fact gastric emptying does not occur with incretin therapy where as it does occur with GLP1 analog therapy used at pharmacologic levels. 事实上,肠促胰岛素治疗不会发生胃排空,而GLP-1的类似物在治疗水平就会发生胃排空。
Incretin system& a new trend for treatment of type 2 diabetes 肠促胰岛素系统&治疗2型糖尿病的新动向
The incretin defect could be named "incretinpathy". 肠促胰岛素缺乏可称为“肠促胰岛素病”。
Incretin mimetics are a new class of treatment in the fight against diabetes. 模拟分泌物是抗糖尿病的一类新的治疗。
The medicine blocks the degradation of incretin hormones that are released in the digestive tact in response to food, and mediate glucose-dependent insulin secretion. 药物阻止在消化食物中释放的肠降血糖素的降解,调节血糖依赖胰岛素的分泌。
Internation Diabetes: And now it's very trended to discuss about incretin, have you ever tried to use incretin? 李文慧博士:目前肠促胰岛素是大家讨论的热点问题,您是否应用过?
Objective: To determine whether the magnitude of the change of the incretin levels and effect is greater after GBP compared to a low caloric diet, after equivalent weight loss. 研究目标:此项研究的目的是确定达到同样的减肥效果胃旁路手术所致肠促胰岛素水平的变化以及影响与低热量饮食相比是否更显著。
Beyond that it becomes less clear; the modulators of incretin axis appear to be promising. 除此以外的结果不够明确。肠促胰岛素调节剂变得很有希望。
At present, several incretin mimetics and DPP-ⅳ inhibitors are undergoing late-stage clinical trials for the treatment of type 2 diabetes. 目前,几种肠促胰岛素类似物和DPP-Ⅳ抑制剂正在进行T2DM治疗的末期临床试验。
Glucagon-like peptide-1 is one of the most important members of incretin, which has an unusual therapeutic potential in type 2 diabetes mellitus and obesity. 胰高血糖素样肽1是重要的肠促胰岛素成员之一,对2型糖尿病及肥胖症有显著疗效。
Effect of Incretin Mimetics and DPP-ⅳ Inhibitors for the Treatment of type 2 Diabetes 肠促胰岛素类似物和DPP-Ⅳ抑制剂在2型糖尿病治疗中的作用
Endogenous incretin hormones glucagon-like peptide-1 ( GLP-1), through activation on its receptor, has various effects on β cell including enhancing glucose-stimulated insulin secretion, differentiation of ductular cell in pancreas to endocrine cells and anti-apoptosis. 内源性激素胰高血糖素样肽1(glucagon-likePeptide1,GLP-1),通过激活其受体,具有刺激葡萄糖依赖的胰岛素分泌、促进胰岛素的生物合成,诱导胰腺导管细胞分化成内分泌细胞和抗凋亡的作用。
Incretin can promote insulin secretion and control postprandial glucose in normal levels. 肠促胰岛素可以促进胰岛素分泌控制餐后血糖处于正常水平。